A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson’s disease in which a patient’s stem cells are reprogrammed to replace dopamine cells in the brain. The clinical trial, based on more than three decades of research, has treated three-of-six participants who will be tracked for more than a year.